[Therapy of acute leukoses].
D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D017053:Infection Control; D007938:Leukemia / Q000188:drug therapy* / Q000401:mortality; D008017:Life Expectancy; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D010357:Patient Isolators; D011239:Prednisolone / Q000627:therapeutic use; D013866:Thioguanine / Q000627:therapeutic use; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D001215:Asparaginase; D013866:Thioguanine; D008727:Methotrexate; D003630:Daunorubicin
Therapie der akuten Leukosen.